PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
39.42%
Revenue growth above 1.5x 5715.T's 8.50%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
53.62%
Positive gross profit growth while 5715.T is negative. John Neff would see a clear operational edge over the competitor.
250.85%
EBIT growth above 1.5x 5715.T's 84.33%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
256.00%
Positive operating income growth while 5715.T is negative. John Neff might view this as a competitive edge in operations.
171.88%
Net income growth under 50% of 5715.T's 597.74%. Michael Burry would suspect the firm is falling well behind a key competitor.
171.96%
EPS growth under 50% of 5715.T's 597.91%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
171.96%
Diluted EPS growth under 50% of 5715.T's 597.91%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.00%
Share reduction while 5715.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 5715.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-90.26%
Negative 10Y revenue/share CAGR while 5715.T stands at 13.71%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-27.58%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-44.20%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
100.00%
10Y OCF/share CAGR in line with 5715.T's 100.00%. Walter Schloss would see both as similarly efficient over the decade.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
101.52%
Net income/share CAGR at 50-75% of 5715.T's 176.73%. Martin Whitman might question if the firm’s product or cost base lags behind.
-49.90%
Negative 5Y net income/share CAGR while 5715.T is 1921.99%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-72.56%
Negative 3Y CAGR while 5715.T is 93.51%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
214.79%
5Y equity/share CAGR above 1.5x 5715.T's 62.55%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
11.06%
Below 50% of 5715.T's 27.00%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.99%
AR growth well above 5715.T's 7.86%. Michael Burry fears inflated revenue or higher default risk in the near future.
16.65%
Inventory growth well above 5715.T's 14.82%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
16.62%
Asset growth above 1.5x 5715.T's 8.30%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.81%
50-75% of 5715.T's 9.13%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
18.95%
Debt growth far above 5715.T's 0.24%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
4.19%
R&D growth of 4.19% while 5715.T is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
0.31%
We expand SG&A while 5715.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.